the aid library

LIST OPTIONS

Filter

6319

Sort by:

Direction:

Download (359)

View PDF (532)

Guidelines for the Management of Multidrug-Resistant Tuberculosis (MDR-TB) in Myanmar

The Republic of the Union of Myanmar, Ministry of Health, Department of Health, National Tuberculosis Programme (2013) C_WHO

Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant TB has been developed and forms part of the Five Year National Strateg... more

Download (1116)

View PDF (1474)

Tuberculosis Infection Control in the Era of Expanding HIV Care and Treatment: Addendum to WHO Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings

Center for Disease Control and Prevention, World Health Organisation (2007)

The goal of this addendum is to help management and staff  minimize the risk of TB transmission at facilities in resource limited settings in which a.) HIV-infected persons receive diagnosis, care, treatment,  and/or support, and b.) there is a high prevalence of HIV infection, both known  and... more

Download (1101)

View PDF (1369)

WHO Operational package for assessing, monitoring and evaluating country pharmaceutical situations

WHO World Health Organization (2007) C_WHO

Guide for coordinators and data collectors - The WHO Operational Package for Assessing, Monitoring and Evaluating Country Pharmaceutical Situations is intended as a useful tool for researchers, policy-makers, planners and others who need to use standardized measurement tools to gather data and other... more

Download (110)

View PDF (141)

WHO Information Series on School Health

World Health Organization (WHO); Unicef; Education International ; et al. World Health Organization (WHO); Unicef; Education International ; et al. (2004) C_WHO

Teachers' Exercise Book for HIV Prevention Document 6.1 This booklet contains all the participatory learning experiences that are included in the Training and Resource Manual on School Health and HIV and AIDS Prevention. It is to be given to all teachers who receive training as part of the EI/WH... more

Download (111)

View PDF (529)

Melarsoprol Resistance in African Trypanosomiasis

Fairlamb, A.H.; Horn, D. Elsevier Ltd. (2018) CC

Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT). Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s. Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher... more

Download (419)

View PDF (1037)

Critically important antimicrobials for human medicine

World Health Organization WHO (2017) C_WHO

5th revised edition. This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.

Download (380)

View PDF (357)

Tanzania: The National Action Plan on AMR 2017-2022

The United Republic of Tanzania - Ministry of Health Community Development Gender Elderly and Children World Health Organization WHO (2017) C_WHO

This National Action Plan addresses actions needed to be taken in order to combat antimicrobial resistance (AMR) in the country. It is obligatory to raise awareness of antimicrobial resistance and promote behavioral change through public communication programmes that targets human, animal and plant... more

Download (345)

View PDF (318)

Module: Essential care and practice

World Health Organization WHO (2015) C_WHO

Overview Learning objectives • Name the general principles of essential care and practice. • Name management principles of priority MNS conditions. • Use effective communication skills in interactions with people with MNS conditions. • Perform assessments for priority MNS conditions. �... more

Download (2048)

View PDF (2666)

WHO Monographs On Selected Medicinal Plants - Volume 1

World Health Organization WHO (1999) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

Download (153)

View PDF (228)

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ... more

Download (2)

View PDF (2)

ENVISION WEbinar: IEC & Social Mobilization Tool Kit Slide Set

USAID, RTI International and Sightsavers (2023) C1

Overview and Practical Experiences from Ethiopia and Uganda. Slide set. This webinar provides an overview of the new IEC & Social Mobilization NTD Tool Kit, which leads users through a step-by-step process to systematically review, revise, develop and adapt current IEC materials and social mobiliza... more

Download (39)

View PDF (39)

Antimicrobial Resistance Surveillance Guidance for the African Region

Africa Center for Disease Control and Prevention (2024) CC

Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and parasites no longer respond to these medicines, ren... more

Download (194)

View PDF (275)

HEARTS. Technical package for cardiovascular disease management in primary health care. Systems of Monitoring

World Health Organization WHO, et al. (2018) C_WHO

Monitoring is a crucial element in any successful programme. It is important to know if health care facilities – and ultimately countries – are meeting the agreed goals and objectives for preventing and managing cardiovascular diseases (CVD). Monitoring is the on-going collection, management ...and use of information to assess whether an activity or programme is proceeding according to plan and/ or achieving defined targets. Not all outcomes of interest can be monitored. Clear outcomes must be identified that relate to the most important changes expected to result from the project and to what is realistic and measurable within the timescale of the project. Once these outcomes have been articulated, indicators can be chosen that best measure whether the desired outcomes are being met. To allow progress to be monitored, this module provides a set of indicators on CVD management. Agreeing on a set of indicators allows countries to compare progress in CVD management and treatment across different districts or subnational jurisdictions, as well as at a facility level, identify where performance can be improved, and track trends in implementation over time. Monitoring these indicators also helps identify problems that may be encountered so that implementation efforts can be redirected. This module starts from the collection of data at facility level, which is then “transferred up” the system: facility-level data are aggregated at subnational level to produce reports that allow tracking of facility and subnational performance over time and allow for comparison among facilities. National-level data are obtained through population-based surveys. Implementing a monitoring system requires action at many levels. At national and subnational levels, staff can determine how best to integrate data elements into existing data collection systems – such as the routine service-delivery data that are collected through facility-level Health Management Information Systems (HMIS). In the facility setting, personnel must be aware of what data are needed. Sample data-collection tools are included, recognizing that countries use different datamanagement systems for HMIS, so the CVD monitoring tools will be adapted to work with the HMIS system being used by the country, such that the indicators can be collected with minimal disruption/work to existing systems and tools more

Download (33)

View PDF (33)

Sport and Asthma

Green, R.; Nagel, F. National Asthma Education Programme (2012) CC2

People with asthma should be encouraged to take part in any sport they choose. If someone with asthma is having difficulty with sport, it means their asthma may not be under control. You will need to see your doctor to review your controller treatment and the way you use your medications in oder to ... more

Download (272)

View PDF (366)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (137)

View PDF (145)

Tuberculosis in the WHO African Region: 2023 progress update - September 2023

World Health Organisation (WHO) (2023) C_WHO

This brief update on tuberculosis (TB) in the African region covers the state of TB in the WHO African region, strategic priorities and targets and the impact of COVID-19 on essential services. This is followed by key figures for the region, the role of WHO in country support and, recognizing the im... more

Download (110)

View PDF (517)

Global programme to eliminate lymphatic filariasis: progress report, 2020 - Weekly Epidemiological Record, 2021, vol. 96, 41 [‎full issue]‎

World Health Organization WHO; Institutional research information sharing iris (2021) C_WHO

Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co... more

Download (554)

View PDF (991)

Infection Prevention and Control Assessment Framework at the Facility Level
recommended

World Health Organization WHO (2018) C_WHO

The Infection Prevention and Control (IPC) Assessment Framework (IPCAF) is a tool to support the implementation of the World Health Organization (WHO) Guidelines on core components of IPC programmes at the acute health care facility level. The user should be familiar with the contents of these guide... more

Download (160)

View PDF (192)

Treatment of Leprosy

Lockwod DN. The International Textbook of Leprosy (2018) CC

This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is a key component of leprosy treatment, as it is vital to prevent the progression of the infection. Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with the ... more

Download (2097)

View PDF (2442)

WHO Monographs On Selected Medicinal Plants - Volume 3

World Health Organization WHO (2007) C_WHO

Therapeutics and COVID-19: living guideline (Arabic) recommended

Infection Prevention and Control Assessment Framework at the Facility Level recommended

Therapeutics and COVID-19: living guideline (Arabic)
recommended

Infection Prevention and Control Assessment Framework at the Facility Level
recommended